PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: RNCOS E-Services (P) Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

RNCOS Releases a New Report on Canadian Generic Drug Market - RNCOS has recently added a new Market Research Report titled,
RNCOS Releases a New Report on Canadian Generic Drug Market

 

NewswireToday - /newswire/ - Delhi, New Delhi, India, 2008/07/09 - RNCOS has recently added a new Market Research Report titled, "Generic Drug Market in Canada" to its report gallery.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Canada represents one of the largest markets for pharmaceuticals in the world, with a huge potential for generics. Generics in 2007 accounted for more then 46% prescriptions and 19% sales out of the total pharmaceutical market. The market is currently being driven by several factors, such as patent expiry of several blockbuster drugs, lower costs, cost containment measures by the government, and rapidly ageing population.

The report thoroughly evaluates the factors that distinguish Canada from all other generic markets both in positive and negative ways. A major factor that differentiates the Canadian generic market from the US and most European markets is the comparatively high price of generics and lower price erosion. This allows manufacturers to fetch better margins from their drugs, and is a major reason which is attracting foreign players to enter this market.

Currently, drugs against chronic diseases occupy most of the pharmaceutical market, with cardiovascular drugs holding the top spot. However, strong growth is expected in other chronic segments also, particularly in cancer and diabetes.

Although the market has huge potential, growth can be significantly hampered by recent government regulations and various other challenges. However, the low cost of generics, coupled with billion dollar drug patent expiries, is expected to enable the generic market to continue its double-digit growth in the next five years.

Key Findings
- The penetration of generics is rapidly increasing in the Canadian pharmaceutical market, with generics expected to account for nearly 26% of the entire pharmaceutical sales by 2012.
- Apotex has been the leader of the Canadian generic market, controlling around 34% of the market in 2006.
- Nearly 5 Million people in Canada will be above 65 years by 2011, increasing the demand for drugs, specifically those for chronic diseases.
- Generics substitution is preferred by pharmacists as they give better returns than branded drugs.
- The top four generic companies presently control more then 70% of the generic market, but the market is expected to undergo more fragmentation in future.
- Projected growth of generics at a CAGR of 14% during 2007-2012 will surpass that of pharmaceutical market at a CAGR 7.6% during the same period.

Key Issues & Facts Analyzed
- Evaluation of past, current and future market trends.
- Discussion about the size and growth of the market.
- Study of various distribution channels prevailing in the market.
- Analysis of healthcare indicators.
- Future prospects of the generic market.
- Profile discussion of key players in this market.
- Analysis of various challenges and opportunities for the market.

Key Players Analyzed
This section provides the overview, key facts, and financial information of prominent players in the Canadian generic market, including Teva Pharmaceutical Industries Limited, Apotex Inc, Ratiopharm GmBH, Pharmascience Inc., etc.

Research Methodology Used

Information Sources
Information has been sourced from books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to over 3000 paid databases.

Analysis Methods
The analysis methods include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis.

About RNCOS
RNCOS, incorporated in the year 2002, is an industry research firm. It has a team of industry experts who analyze data collected from credible sources. They provide industry insights and analysis that helps corporations to take timely and accurate business decision in today's globally competitive environment.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: RNCOS E-Services (P) Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


RNCOS Releases a New Report on Canadian Generic Drug Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Shushmul Maheshwari 
+91 12 04224700 press[.]rncos.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any RNCOS E-Services (P) Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From RNCOS E-Services (P) Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MagLar, Inc.

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)